bioAffinity Technologies, Inc. (BIAF)

The past six months have seen several events impacting bioAffinity Technologies' stock price. The company effected a 1-for-30 reverse stock split on September 19, 2025. In November 2025, bioAffinity Technologies reported its third-quarter earnings, which missed analyst estimates, leading to a dip in the stock price. Despite this, the company announced an increase in CyPath® Lung tests processed in October 2025. In December 2025, there was a transfer of ownership for Village Oaks Pathology and a special shareholder meeting was adjourned due to a lack of quorum. Earlier in this six-month period, the company's stock declined following its second-quarter earnings report, which also missed revenue targets. Overall, the stock price has experienced a significant decline over the last six months and the past year. However, insider sentiment for BIAF is positive, with 15 different insiders having made recent acquisitions.

There is no indication of significant demand seasonality for bioAffinity Technologies' products and services. Instead, the company has reported continued sales growth for its CyPath® Lung diagnostic test, with the number of tests processed increasing steadily each month and more than doubling since the start of 2025. The company also noted consistent month-over-month and quarter-over-quarter growth in CyPath® Lung sales during the first 10 months of 2025.

bioAffinity Technologies, Inc. is a development-stage biotechnology company focused on non-invasive, early-stage cancer diagnosis and targeted cancer treatment. The company operates in the Healthcare sector, specifically in the Diagnostics & Research and Medical Diagnostics & Research industries. Its primary product is CyPath® Lung, a non-invasive diagnostic test for the early detection of lung cancer. The company also develops targeted cancer therapeutics using technology that targets cancer cells. bioAffinity Technologies operates through two segments: Diagnostic Research and Development, and Laboratory Services.

bioAffinity Technologies, Inc. is headquartered in San Antonio, Texas, United States. The company's operations and commercialization efforts for CyPath® Lung are primarily focused within the United States. While the company aims to strengthen international intellectual property protection and expand global commercialization potential for CyPath® Lung, specific current international operational footprints beyond the U.S. are not detailed.

While direct statements on overall brand reputation are not explicitly provided, several factors contribute to bioAffinity Technologies' standing. The consistent growth in CyPath® Lung test volume, coupled with physicians increasingly recognizing its clinical value, suggests a positive reputation for its flagship product within the medical community. The company's laboratory, Precision Pathology Laboratory Services, maintaining CAP accreditation also enhances its credibility and reputation for quality. However, the significant decline in the company's stock price over the past year could potentially impact its reputation among investors.

bioAffinity Technologies, Inc. has a number of institutional owners and shareholders. As of September 30, 2025, major institutional owners include Sabby Management, Llc, IFP Advisors, Inc., Scientech Research LLC, Tower Research Capital LLC (TRC), Allworth Financial LP, Bank Of America Corp /de/, Citigroup Inc, Larson Financial Group LLC, and Fmr Llc. Other institutional investors that have held shares include Morgan Stanley, Sheaff Brock Investment Advisors LLC, Renaissance Technologies LLC, and Ground Swell Capital LLC. Approximately 1.64% of bioAffinity Technologies' stock is owned by institutional investors.